In Silico Design of a Novel Multi-Epitope Peptide Vaccine Against Hepatocellular Carcinoma

Author:

Dehbarez Fatemeh Motamedi1,Nezafat Navid2,Mahmoodi Shirin1

Affiliation:

1. Department of Medical Biotechnology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran

2. Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Background: Hepatocellular Carcinoma (HCC) is a prevalent cancer in the world. As yet, there is no medication for complete treatment of HCC. Objective: There is a critical need to search for an innovative therapy for HCC. Recently, multiepitope vaccines have been introduced as effective immunotherapy approach against HCC. Methods: In this research, several immunoinformatics methods were applied to create an original multi-epitope vaccine against HCC consisting of CD8+ cytolytic T lymphocytes (CTLs) epitopes selected from α- fetoprotein (AFP), glypican-3 (GPC3), aspartyl-β-hydroxylase (ASPH); CD4+ helper T lymphocytes (HTLs) epitopes from tetanus toxin fragment C (TTFC), and finally, two tandem repeats of HSP70407-426 were used which stimulated strong innate and adaptive immune responses. All the mentioned parts were connected together by relevant linkers. Results: According to physicochemical, structural, and immunological results, the designed vaccine is stable, non-allergen, antigen; it also has a high-quality 3D structure, and numerous linear and conformational B cell epitopes, whereby this vaccine may stimulate efficient humoral immunity. Conclusion: Center on the collected results, the designed vaccine potentially can induce cellular and humoral immune responses in HCC cases; nonetheless, the efficiency of vaccine must be approved within in vitro and in vivo immunological analyzes.

Funder

Fasa University of Medical Sciences

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Reference75 articles.

1. Tsuchiya,N.; Yoshikawa,T.; Fujinami,N.; Saito,K.; Mizuno,S.; Sawada,Y.; Endo,I.; Nakatsura, T. Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. OncoImmunology. 2017,6(10),e1346764. http://dx.doi.org/10.1080/2162402X.2017.1346764 PMID: 29123959

2. Liu,Q.; Yang,Y.; Tan,X.; Tao,Z.; Adah,D.; Yu,S.; Lu,J.; Zhao,S.; Qin,L.; Qin,L.; Chen, X. Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector. Onco-target. 2017,8(15),24785-24796. http://dx.doi.org/10.18632/oncotarget.15806 PMID: 28445973

3. Wang,Q.; Luan,W.; Warren,L.; Kadri,H.; Kim, K.W.; Goz,V.; Blank,S.; Isabel Fiel,M.; Hiotis, S.P. Autologous tumor cell ly-sate-loaded dendritic cell vaccine inhibited tumor progression in an orthotopic murine model for hepatocellular carcinoma. Ann. Surg. Oncol. 2016,23(5) (Suppl. 5),574-582. http://dx.doi.org/10.1245/s10434-015-5035-9 PMID: 26786094

4. Arzumanyan,A.; Reis, H.M.; Feitelson, M.A. Pathogenic mecha-nisms in HBV-and HCV-associated hepatocellular carcinoma. Nat. Rev. Cancer. 2013,13(2),123-135. http://dx.doi.org/10.1038/nrc3449 PMID: 23344543

5. Llovet, J.M.; Ricci,S.; Mazzaferro,V.; Hilgard,P.; Gane,E.; Blanc, J-F.; de Oliveira, A.C.; Santoro,A.; Raoul, J-L.; Forner,A.; Schwartz,M.; Porta,C.; Zeuzem,S.; Bolondi,L.; Greten, T.F.; Galle, P.R.; Seitz, J.F.; Borbath,I.; H?ussinger,D.; Giannaris,T.; Shan,M.; Moscovici,M.; Voliotis,D.; Bruix, J. SHARP Investiga-tors Study Group. Sorafenib in advanced hepatocellular carcinoma, N. Engl, J. Med. 2008,359(4),378-390. http://dx.doi.org/10.1056/NEJMoa0708857 PMID: 18650514

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3